Journal
BONE
Volume 70, Issue -, Pages 93-101Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2014.07.033
Keywords
Bone healing; Nonunion; Cell therapy; Clinical trials; MSCs
Categories
Funding
- European Commission, Seventh Framework Programme (FP7), through the REBORNE Project [241879]
- Spanish General Directorate on Scientific and Technological Research, Ministry of Economy and Competitiveness [SAF2012-40149-C02-01]
Ask authors/readers for more resources
Bone fracture healing impairment related to mechanical problems has been largely corrected by advances in fracture management. Better protocols, more strict controls of time and function, and hardware and surgical technique evolution have contributed to better prognosis, even in complex fractures. However, atrophic nonunion persists in clinical cases where, for different reasons, the osteogenic capability is impaired. When this is the case, a better understanding of the basic mechanisms under bone repair and augmentation techniques may put in perspective the current possibilities and future opportunities. Among those, cell therapy particularly aims to correct this insufficient osteogenesis. However, the launching of safe and efficacious cell therapies still requires substantial amount of research, especially clinical trials. This review will envisage the current clinical trials on bone healing augmentation based on cell therapy, with the experience provided by the REBORNE Project, and the insight from investigator-driven clinical trials on advanced therapies towards the future. This article is part of a Special Issue entitled Stem Cells and Bone. (C) 2014 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available